Published on:

February 2013 Medication Label Changes

Last month brought changes to thirty-five (35) medical product labels (up from 27 changes in January), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

For a complete detailed accounting of the label changes, refer to the summary of meds. By clicking onto the drug name, you can view the detailed summary, which will identify the safety labeling section and revised subsection, and a brief summary of the new or modified safety information.

The following medications have been affected:

Aceon (perindopril erbumine)
Aromasin (exemestane)
Chantix (varenicline)
Dextrose 5% in Lactated Ringer’s Injection
Ellence (epirubicin hydrochloride)
FML (fluorometholone)
FML Forte (fluorometholone)
Intelence (etravirine)
Kapvay (clonidine hydrochloride)
Lexiva (fosamprenavir calcium)
Lidocaine Hydrochloride and 5% Dextrose
Niaspan (niacin extended-release)
Prezista (darunavir)
Prinivil (lisinopril)
Prinzide (lisinopril hydrochlorothiazide)
Qualaquin (quinine sulfate)
Rifadin (rifampin) and  Rifadin IV (rifampin)
Rifater (rifampin, isoniazid, and pyrazinamide)
Rythmol SR (propafenone HCl)
Selzentry (maraviroc)
Simcor (niacin ER/simvastatin)
Tricor (fenofibrate)
Xgeva (denosumab)
Zithromax (azithromycin)
Zmax (azithromycin extended-release)
Zortress (everolimus)